{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:26Z","timestamp":1787041706175,"version":"build-2736575974"},"reference-count":242,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119095","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:33:22Z","timestamp":1782491602000},"page":"119095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["2-Pyridone as privileged scaffold: Advances in drug design and structural modification"],"prefix":"10.1016","volume":"317","author":[{"given":"Yichun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9767-6825","authenticated-orcid":false,"given":"Guangjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119095_bib1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/molecules25081909","article-title":"A review on recent advances in nitrogen-containing molecules and their biological applications","volume":"25","author":"Kerru","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119095_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108709","article-title":"A comprehensive review on the role of nitrogen containing heterocycles in overcoming ABC transporter mediated multidrug resistance in cancer","volume":"163","author":"Naik","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib3","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/molecules29102232","article-title":"N-Heterocycles as promising antiviral agents: a comprehensive overview","volume":"29","author":"Ahmad","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119095_bib4","doi-asserted-by":"crossref","first-page":"34965","DOI":"10.1039\/D2RA07056A","article-title":"Bioactive 2-pyridone-containing heterocycle syntheses using multicomponent reactions","volume":"12","author":"Hurtado-Rodr\u00edguez","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119095_bib5","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm801331y","article-title":"The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists","volume":"52","author":"Laurence","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib6","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-Pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2026.119095_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011212","article-title":"New pyridone-based derivatives as cannabinoid receptor type 2 agonists","volume":"22","author":"Fa\u00fandez-Parraguez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2026.130654","article-title":"Synthesis and biological evaluation of novel pyridone derivatives containing 1,3,4-thiadiazol as potential anticancer agents","volume":"137","author":"Long","year":"2026","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119095_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127849","article-title":"Pyridones in drug discovery: recent advances","volume":"38","author":"Zhang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119095_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117953","article-title":"Fungal 4-Hydroxy-2-Pyridone alkaloids: structures, synthesis, biosynthesis, and bioactivities (2010-2024)","volume":"297","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2021.101259","article-title":"Recent advances in chemistry and pharmacological aspects of 2-pyridone scaffolds","volume":"25","author":"Amer","year":"2021","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119095_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acs.molpharmaceut.4c01267","article-title":"Nano-based strategies aiming at tumor microenvironment for improved cancer therapy","volume":"22","author":"Liu","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119095_bib13","article-title":"Supramolecular nanomedicine in the intelligent cancer therapy: recent advances and future","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1335019","article-title":"Research progress of biomineralization for the diagnosis and treatment of malignant tumors","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib15","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/pharmaceutics14101990","article-title":"Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications","volume":"14","author":"Wu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119095_bib16","first-page":"421","article-title":"Progression of central nervous system metastases in advanced nonsmall cell lung cancer patients effectively treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor","volume":"33","author":"Yu","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ejmech.2026.119095_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101176","article-title":"Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies","volume":"78","author":"Wu","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2026.119095_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2013.06.002","article-title":"Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins","volume":"40","author":"Remon","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2026.119095_bib19","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/1871520622666220408090541","article-title":"Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: a review","volume":"22","author":"Unnisa","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib20","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119095_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acsmedchemlett.5b00428","article-title":"Pyridones as highly selective, noncovalent inhibitors of T790M double mutants of EGFR","volume":"7","author":"Bryan","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib22","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.2147\/IJN.S502144","article-title":"Advancements in cell membrane-derived biomimetic nanotherapeutics for breast cancer","volume":"20","author":"Zeng","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119095_bib23","article-title":"Emerging opportunities to treat drug-resistant breast cancer: discovery of novel small-molecule inhibitors against different targets","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2014.0026","article-title":"The role of cytokines in breast cancer development and progression","volume":"35","author":"Esquivel-Vel\u00e1zquez","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib25","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.3390\/cancers15225383","article-title":"Cytokine profile in lung cancer patients: anti-tumor and oncogenic cytokines","volume":"15","author":"Essogmo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119095_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119095_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118165","article-title":"Microwave-assisted one-pot green synthesis, ADMET profiling, DFT, and molecular docking of novel 3-cyano-2-pyridone derivatives as dual EGFR and cytokine (TNF-\u03b1, IL-6) inhibitors","volume":"300","author":"Lotfy","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: from mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2026.119095_bib29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/molecules24061140","article-title":"DHFR inhibitors: reading the past for discovering novel anticancer agents","volume":"24","author":"Raimondi","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119095_bib30","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1002\/slct.202102555","article-title":"An insight into synthetic strategies and recent developments of dihydrofolate reductase inhibitors","volume":"6","author":"Chawla","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2026.119095_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117751","article-title":"Discovery and optimization of 2-pyridones as dual h-DHFR\/EGFRTK inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer","volume":"294","author":"Ragab","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.31083\/ph.2022.2422","article-title":"Effect of cyasterone on intestinal flora in a BRAFV600E-mutant mouse model of colorectal cancer","volume":"77","author":"Xiong","year":"2022","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejmech.2026.119095_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1764","article-title":"A comprehensive overview of the molecular features and therapeutic targets in BRAFV600E-mutant colorectal cancer","volume":"14","author":"Gu","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119095_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/receptors3010005","article-title":"Role and function of receptor tyrosine kinases in BRAF mutant cancers","volume":"3","author":"Biersack","year":"2024","journal-title":"Receptor"},{"key":"10.1016\/j.ejmech.2026.119095_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17425247.2021.1825377","article-title":"Targeted drug therapy in non-small cell lung cancer: clinical significance and possible solutions-part I","volume":"18","author":"Upadhya","year":"2021","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.ejmech.2026.119095_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119095_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109329","article-title":"Design, synthesis, apoptotic antiproliferative, and antioxidant activities of a new series of 2-mercaptobenzimidazole\/3-cyanopyridin-2-one hybrids as dual EGFR\/BRAFV600E inhibitors","volume":"168","author":"Al-Wahaibi","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib38","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/MCB.00147-14","article-title":"The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling","volume":"34","author":"Cen","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119095_bib39","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-15-0544","article-title":"Activation of pim kinases is sufficient to promote resistance to MET small-molecule inhibitors","volume":"75","author":"An","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2018.12.015","article-title":"PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway","volume":"444","author":"Cao","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib41","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.21037\/tlcr-20-681","article-title":"SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer","volume":"9","author":"Attili","year":"2020","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.ejmech.2026.119095_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106988","article-title":"Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: design, synthesis, SAR and in silico study","volume":"143","author":"Mohamady","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1602654","article-title":"Case report: locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib","volume":"16","author":"Xue","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib44","article-title":"Case report: a novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib45","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119095_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802\/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib","volume":"9","author":"Ignatius Ou","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.119095_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111734","article-title":"Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants","volume":"183","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib48","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4103\/njcp.njcp_826_24","article-title":"Autoimmune hemolytic anemia in non-hodgkin's lymphoma: pathogenesis, diagnosis, and management","volume":"28","author":"Suryana","year":"2025","journal-title":"Niger. J. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119095_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119095_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153802","article-title":"Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo","volume":"93","author":"Song","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119095_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.70082","article-title":"Structural and functional insights into lyn kinase: from immune regulation to therapeutic targeting","volume":"127","author":"Khan","year":"2026","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2026.119095_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ejmech.2014.09.018","article-title":"4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies","volume":"86","author":"Puig de la Bellacasa","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13577-021-00656-3","article-title":"A systematic review on active sites and functions of PIM-1 protein","volume":"35","author":"Zhao","year":"2022","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ejmech.2026.119095_bib54","first-page":"265","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review","volume":"17","author":"Jie","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejmech.2026.119095_bib55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13543776.2024.2365411","article-title":"PIM kinase inhibitors: an updated patent review (2016-present)","volume":"34","author":"Sharma","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119095_bib56","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bmcl.2006.12.086","article-title":"Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase","volume":"17","author":"Cheney","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119095_bib57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejmech.2017.04.024","article-title":"Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities","volume":"134","author":"Abouzid","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106122","article-title":"Development of novel cyanopyridines as PIM-1 kinase inhibitors with potent anti-prostate cancer activity: synthesis, biological evaluation, nanoparticles formulation and molecular dynamics simulation","volume":"129","author":"Ibrahim","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108564","article-title":"Discovery of new pyridine-O-propargyl\/1,2,3-triazole hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3\/7 activation capabilities","volume":"162","author":"Abdelaziz","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119095_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/d41573-019-00202-9","article-title":"PKMYT1: a forgotten member of the WEE1 family","volume":"19","author":"Asquith","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119095_bib62","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","article-title":"Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306","volume":"65","author":"Szychowski","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib63","doi-asserted-by":"crossref","first-page":"17997","DOI":"10.1021\/acs.jmedchem.4c01619","article-title":"Targeting protein kinase, membrane-associated tyrosine\/threonine 1 (PKMYT1) for precision cancer therapy: from discovery to clinical trial","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117025","article-title":"Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer","volume":"281","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309261121","article-title":"Cell cycle plasticity underlies fractional resistance to palbociclib in ER+\/HER2- breast tumor cells","volume":"121","author":"Zikry","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119095_bib66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119095_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104324","article-title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions","volume":"196","author":"Gerosa","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119095_bib68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/17460441.2024.2376655","article-title":"Inhibitors and PROTACs of CDK2: challenges and opportunities","volume":"19","author":"Zeng","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119095_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117503","article-title":"Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer","volume":"290","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115842","article-title":"Unraveling the interplay between RAS\/RAF\/MEK\/ERK signaling pathway and autophagy in cancer: from molecular mechanisms to targeted therapy","volume":"217","author":"Huang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115988","article-title":"Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS\/MEK\/ERK and PI3K\/AKT signaling pathways","volume":"441","author":"Fu","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib72","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","article-title":"Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy","volume":"12","author":"Pan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119095_bib73","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11030-020-10088-0","article-title":"Structure-activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety","volume":"25","author":"Yang","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.119095_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2555510","article-title":"Advances in ERK1\/2 inhibition: a medicinal chemistry perspective on structure and regulation","volume":"40","author":"Sah","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib75","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/jm501921k","article-title":"Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1\/2","volume":"58","author":"Ren","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib76","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1021\/acs.jmedchem.6b00389","article-title":"Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1\/2 (ERK1\/2) inhibitor in early clinical development","volume":"59","author":"Blake","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature21036","article-title":"Translation from unconventional 5' start sites drives tumour initiation","volume":"541","author":"Sendoel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119095_bib78","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2174\/0929867324666170203123427","article-title":"Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors","volume":"24","author":"Dreas","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib79","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.2174\/0109298673260837231120101508","article-title":"MNK: a novel promising target for cancer immunotherapy","volume":"32","author":"Shu","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib80","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acs.jmedchem.1c00368","article-title":"Update on the development of MNK inhibitors as therapeutic agents","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib81","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejmech.2015.03.032","article-title":"Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d] pyrimidine derivatives as potent Mnk inhibitors: synthesis, structureeactivity relationship analysis and biological evaluation","volume":"95","author":"Yu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib82","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.jmedchem.7b01795","article-title":"Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1\/2) inhibition","volume":"61","author":"Reich","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib83","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2020.38.15_suppl.3112","article-title":"A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment","volume":"38","author":"El-Khoueiry","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119095_bib84","doi-asserted-by":"crossref","first-page":"66339","DOI":"10.1021\/acsami.5c15987","article-title":"Exosome-mediated RUNX3 DNA delivery for lung cancer therapy","volume":"17","author":"Jeon","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2026.119095_bib85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1573406415666190712120611","article-title":"Synthesis of N-Substituted benzamide derivatives and their evaluation as antitumor agents","volume":"16","author":"Chen","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib86","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s10637-018-0651-4","article-title":"Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma","volume":"37","author":"Zhong","year":"2019","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119095_bib87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/cmdc.201300393","article-title":"Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control","volume":"9","author":"Cho","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119095_bib88","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1021\/acs.jmedchem.5b00062","article-title":"Discovery of orally available runt-related transcription factor 3 (RUNX3) modulators for anticancer chemotherapy by epigenetic activation and protein stabilization","volume":"58","author":"Yang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib89","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejmech.2016.11.055","article-title":"Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators","volume":"126","author":"Song","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119095_bib90","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/med.21859","article-title":"Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives","volume":"42","author":"Feng","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119095_bib91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119095_bib92","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/13543776.2022.2115354","article-title":"BET inhibitors: an updated patent review (2018-2021)","volume":"32","author":"Chen","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119095_bib93","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1021\/acs.jmedchem.7b00017","article-title":"Fragment-based, structure-enabled discovery of novel pyridones and pyridone macrocycles as potent bromodomain and extra-terminal domain (BET) family bromodomain inhibitors","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119095_bib95","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the first BRD4 second bromodomain (BD2)-selective inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib96","doi-asserted-by":"crossref","first-page":"9093","DOI":"10.1021\/acs.jmedchem.0c00796","article-title":"The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor","volume":"63","author":"Seal","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126031","article-title":"Current approaches to overcome the limit of TRAIL-based treatment in colorectal cancer: from fusion protein to nano-delivery platform","volume":"683","author":"Chen","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119095_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116101","article-title":"HER2 targeted therapy in colorectal cancer: current landscape and future directions","volume":"223","author":"Chen","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.aao2793","article-title":"SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis","volume":"360","author":"Muhar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119095_bib100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10637-020-01014-0","article-title":"The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway","volume":"39","author":"Lei","year":"2021","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.119095_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118573","article-title":"Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer","volume":"305","author":"Fang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib102","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/IJN.S189871","article-title":"Targeting EZH2 for glioma therapy with a novel nanoparticle-siRNA complex","volume":"14","author":"Wang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119095_bib103","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11030-018-9903-7","article-title":"Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity","volume":"23","author":"Feng","year":"2019","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.119095_bib104","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual inhibition of EZH2 and EZH1 sensitizes PRC2-Dependent tumors to proteasome inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib105","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","article-title":"Structure-activity relationship studies for enhancer of Zeste Homologue 2 (EZH2) and enhancer of Zeste Homologue 1 (EZH1) inhibitors","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115493","article-title":"Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo","volume":"210","author":"Zhu","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib107","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/13543776.2023.2206018","article-title":"A patent review of EZH2 inhibitors from 2017 and beyond","volume":"33","author":"Wan","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119095_bib108","article-title":"Novel agents and therapeutic advances in T cell lymphoma","volume":"27","author":"Shirouchi","year":"2026","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2026.119095_bib109","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/13543776.2025.2483399","article-title":"An updated patent review of EZH2 inhibitors (2024-present)","volume":"35","author":"Wan","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119095_bib110","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1021\/acs.jmedchem.6b00515","article-title":"Design and synthesis of pyridone-containing 3,4-Dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of Zeste Homolog 2 (EZH2) inhibitors","volume":"59","author":"Kung","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.119095_bib112","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acsmedchemlett.0c00045","article-title":"Design, synthesis, and pharmacological evaluation of second generation EZH2 inhibitors with long residence time","volume":"11","author":"Khanna","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106122","article-title":"Development of novel cyanopyridines as PIM-1 kinase inhibitors with potent anti-prostate cancer activity: synthesis, biological evaluation, nanoparticles formulation and molecular dynamics simulation","volume":"129","author":"Ibrahim","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119095_bib115","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119095_bib116","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-Aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119095_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115825","article-title":"Discovery of dihydropyridinone derivative as a covalent EZH2 degrader","volume":"261","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib118","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1021\/acs.jmedchem.3c00504","article-title":"Discovery of a new-generation S-Adenosylmethionine-Noncompetitive covalent inhibitor targeting the lysine methyltransferase enhancer of Zeste Homologue 2","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib119","article-title":"Functional tumor-derived exosomes in NSCLC progression and clinical implications","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1441233","article-title":"Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses","volume":"15","author":"Luan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib121","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","article-title":"Tumour and microenvironment crosstalk in NSCLC progression and response to therapy","volume":"22","author":"Rahal","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119095_bib122","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"The interplay between HIF-1\u03b1 and EZH2 in lung cancer and dual-targeted drug therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107419","article-title":"2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1\u03b1 and EZH2 for the treatment of lung cancer","volume":"147","author":"Xu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib124","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11030-025-11185-8","article-title":"Identification of low-toxicity DNA topoisomerase I inhibitors with potential blood-brain barrier penetrability for glioblastoma therapy: structure-based virtual screening reveals promising novel Scaffolds","volume":"30","author":"Li","year":"2026","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.119095_bib125","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the potential of camptothecin: exploring innovative strategies for structural modification and therapeutic advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bbrc.2016.02.015","article-title":"Low toxic and high soluble camptothecin derivative 2-47 effectively induces apoptosis of tumor cells in vitro","volume":"472","author":"Zhou","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119095_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109171","article-title":"Camptothecin 20(S)-sulfonyl amidine derivative inhibits gastric cancer cell proliferation by targeting topoisomerase I to trigger the DNA damage-apoptosis cascade","volume":"166","author":"Si","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154550","article-title":"Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton","volume":"109","author":"Yan","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119095_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106340","article-title":"Discovery of potent microtubule-destabilizing agents targeting for colchicine site by virtual screening, biological evaluation, and molecular dynamics simulation","volume":"180","author":"Zhang","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib130","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms26157652","article-title":"Microtubule-targeting agents: advances in tubulin binding and small molecule therapy for gliomas and neurodegenerative diseases","volume":"26","author":"Ezzo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111728","article-title":"Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer","volume":"184","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119095_bib132","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2014.04.037","article-title":"Structure of a RING E3 trapped in action reveals ligation mechanism for the ubiquitin-like protein NEDD8","volume":"157","author":"Scott","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119095_bib133","first-page":"1000","article-title":"MicroRNA-302 inhibits cell migration and invasion in cervical cancer by targeting DCUN1D1","volume":"16","author":"Jiang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2026.119095_bib134","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41467-017-01243-7","article-title":"A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119095_bib135","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/acs.jmedchem.7b01455","article-title":"High-affinity peptidomimetic inhibitors of the DCN1-UBC12 protein-protein interaction","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib136","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.1021\/acs.jmedchem.9b00410","article-title":"Discovery of novel pyrazolo-pyridone DCN1 inhibitors controlling cullin Neddylation","volume":"62","author":"Kim","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib137","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1021\/acs.jmedchem.1c00035","article-title":"Improvement of oral bioavailability of pyrazolo-pyridone inhibitors of the interaction of DCN1\/2 and UBE2M","volume":"64","author":"Kim","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib138","doi-asserted-by":"crossref","first-page":"51107","DOI":"10.18632\/oncotarget.9812","article-title":"A novel CBL-Bflox\/flox mouse model allows tissue-selective fully conditional CBL\/CBL-B double-knockout: CD4-Cre mediated CBL\/CBL-B deletion occurs in both T-cells and hematopoietic stem cells","volume":"32","author":"Goetz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119095_bib139","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nm.4141","article-title":"Targeting CBLB as a potential therapeutic approach for disseminated candidiasis","volume":"22","author":"Xiao","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119095_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117488","article-title":"Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors","volume":"290","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib141","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2008.07644.x","article-title":"Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion","volume":"101","author":"Swietach","year":"2008","journal-title":"BJU Int."},{"key":"10.1016\/j.ejmech.2026.119095_bib142","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyss\u00e9gur","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119095_bib143","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejmech.2016.04.009","article-title":"Design and synthesis of some novel 4-Chloro-N-(4-(1-(2-(2-cyanoacetyl)hydrazono)ethyl)phenyl) benzenesulfonamide derivatives as anticancer and radiosensitizing agents","volume":"117","author":"Ghorab","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib144","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41401-024-01472-9","article-title":"Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery","volume":"46","author":"Shen","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119095_bib145","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tem.2015.07.007","article-title":"The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease","volume":"26","author":"Mazier","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2026.119095_bib146","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2018.05.019","article-title":"Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system","volume":"154","author":"Chicca","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib147","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejmech.2017.12.038","article-title":"Design, synthesis and biological evaluations of novel pyridone-thiazole hybrid molecules as antitumor agents","volume":"145","author":"Xie","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib148","article-title":"Self-stabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma","volume":"5","author":"Zhang","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib149","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1021\/acs.molpharmaceut.8b00525","article-title":"Discovery and characterization of 4-Hydroxy-2-pyridone derivative sambutoxin as a potent and promising anticancer drug candidate: activity and molecular mechanism","volume":"15","author":"Li","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119095_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116314","article-title":"4-Hydroxy-2-pyridone derivatives with antitumor activity produced by mangrove endophytic fungus talaromyces sp. CY-3","volume":"269","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib151","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3390\/pharmaceutics16121549","article-title":"Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance","volume":"16","author":"Meng","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119095_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155475","article-title":"Mitigating phospholipid peroxidation of macrophages in stress-induced tumor microenvironment by natural ALOX15\/PEBP1 complex inhibitors","volume":"128","author":"Luo","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119095_bib153","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.70044","article-title":"Repurposing asparaginase therapy to target cisplatin-resistant cancer cells","volume":"39","author":"Wang","year":"2025","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib154","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13148-025-01961-6","article-title":"Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms","volume":"17","author":"Yu","year":"2025","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2026.119095_bib155","article-title":"N-Phenyl-2-Pyridone-Derived endoperoxide suppressing both lung cancer and idiopathic pulmonary fibrosis progression by three-pronged action","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119095_bib156","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1021\/acs.jmedchem.5c03032","article-title":"PlatinumIV complex enabling multiple and potent tumor microenvironment remodeling for cancer chemo-immunotherapy","volume":"69","author":"Sun","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib157","doi-asserted-by":"crossref","first-page":"36459","DOI":"10.1039\/D1RA06238G","article-title":"Bacterial virulence factors: a target for heterocyclic compounds to combat bacterial resistance","volume":"58","author":"Abd El-Aleam","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119095_bib158","article-title":"Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options","volume":"24","author":"Zhou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib159","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1021\/jm100470t","article-title":"Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity","volume":"53","author":"Chorell","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ejmech.2012.06.018","article-title":"Design, synthesis and evaluation of triazole functionalized ring-fused 2-pyridones as antibacterial agents","volume":"54","author":"Bengtsson","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib161","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/jm2014875","article-title":"Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections","volume":"55","author":"Montgomery","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2024.109057","article-title":"LpxC inhibition: potential and opportunities with carbohydrate scaffolds","volume":"537","author":"Amudala","year":"2024","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib163","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.bmcl.2017.10.006","article-title":"4-Hydroxy-2-pyridones: discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis","volume":"27","author":"Arnold","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119095_bib164","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1021\/acs.jmedchem.8b00114","article-title":"Discovery and optimization of indolyl-containing 4-Hydroxy-2-Pyridone type II DNA topoisomerase inhibitors active against multidrug resistant gram-negative bacteria","volume":"61","author":"Gerasyuto","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106195","article-title":"Epigenetic changes in Mycobacterium tuberculosis and its host provide potential targets or biomarkers for drug discovery and clinical diagnosis","volume":"179","author":"Sui","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib166","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejmech.2014.06.004","article-title":"Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs","volume":"82","author":"Desai","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib167","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.119095_bib168","doi-asserted-by":"crossref","first-page":"269ra3","DOI":"10.1126\/scitranslmed.3010597","article-title":"Direct inhibitors of InhA are active against Mycobacterium tuberculosis","volume":"7","author":"Manjunatha","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119095_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112450","article-title":"Synthesis and structure activity relationships of cyanopyridone-based anti-tuberculosis agents","volume":"201","author":"Jian","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib170","doi-asserted-by":"crossref","first-page":"11056","DOI":"10.1021\/acs.jmedchem.3c00358","article-title":"Design, synthesis, and evaluation of novel \u03942-Thiazolino 2-Pyridone derivatives that potentiate isoniazid activity in an isoniazid-resistant Mycobacterium tuberculosis mutant","volume":"66","author":"Sarkar","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115534","article-title":"Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: design, synthesis and biological evaluation","volume":"257","author":"Ibrahim","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116806","article-title":"Design and synthesis of Thieno[3, 2-b]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase","volume":"279","author":"Liang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib173","doi-asserted-by":"crossref","first-page":"30023","DOI":"10.1021\/acsomega.0c04424","article-title":"Novel synthesis and antiviral evaluation of new benzothiazole-bearing N-Sulfonamide 2-Pyridone derivatives as USP7 enzyme inhibitors","volume":"5","author":"Azzam","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119095_bib174","first-page":"67","article-title":"HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review","volume":"26","author":"Blanco-Ar\u00e9valo","year":"2024","journal-title":"AIDS Rev."},{"key":"10.1016\/j.ejmech.2026.119095_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114581","article-title":"Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability","volume":"240","author":"Zhao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib176","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1016\/j.apsb.2023.07.008","article-title":"Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility","volume":"13","author":"Zhao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119095_bib177","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/med.21941","article-title":"Research progress in spike mutations of SARS-CoV-2 variants and vaccine development","volume":"43","author":"He","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119095_bib178","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1021\/acs.jmedchem.4c02172","article-title":"Structure-based optimization of pyridone \u03b1-Ketoamides as inhibitors of the SARS-CoV-2 main protease","volume":"68","author":"Akula","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155101","article-title":"Natural products for the treatment of neurodegenerative diseases","volume":"121","author":"Cui","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119095_bib180","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70176","article-title":"Alzheimer's disease: treatment challenges for the future","volume":"169","author":"Hardy","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2026.119095_bib181","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/ml1000799","article-title":"The discovery of pyridone and pyridazone heterocycles as \u03b3-Secretase modulators","volume":"1","author":"Huang","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib182","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1021\/acs.jmedchem.4c00580","article-title":"Discovery of clinical candidate PF-06648671: a potent \u03b3-Secretase modulator for the treatment of Alzheimer's disease","volume":"67","author":"Pettersson","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib183","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.apsb.2025.02.035","article-title":"Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged \u03b2-amyloid nanoscavenger for Alzheimer's disease therapy","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119095_bib184","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1567205020666230612155953","article-title":"BACE-1 inhibitors targeting Alzheimer's disease","volume":"20","author":"Monteiro","year":"2023","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113779","article-title":"From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-alzheimer lead with disease-modifying and cognition-enhancing effects","volume":"225","author":"Pont","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib186","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2174\/1871527323666230811093126","article-title":"Phosphodiesterase 2 and its isoform A as therapeutic targets in the central nervous system disorders","volume":"23","author":"Metkar","year":"2024","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejmech.2026.119095_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118302","article-title":"Discovery of novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one derivatives as PDE2 inhibitors with Alzheimer's disease therapeutic potential","volume":"302","author":"Yang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib188","doi-asserted-by":"crossref","DOI":"10.1042\/NS20210004","article-title":"Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease","volume":"6","author":"Dwomoh","year":"2022","journal-title":"Neuronal Signaling"},{"key":"10.1016\/j.ejmech.2026.119095_bib189","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acs.jmedchem.5b01562","article-title":"4-Phenylpyridin-2-one derivatives: a novel class of positive allosteric modulator of the M1 muscarinic acetylcholine receptor","volume":"59","author":"Mistry","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib190","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.drudis.2022.04.003","article-title":"Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases","volume":"27","author":"Liu","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119095_bib191","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3390\/ijms25073845","article-title":"Huntington's disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119095_bib192","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1021\/acs.jmedchem.1c00114","article-title":"Structure-based exploration of selectivity for ATM inhibitors in Huntington's disease","volume":"64","author":"Van de Po\u00ebl","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib193","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41591-022-02197-0","article-title":"New and emerging approaches to treat psychiatric disorders","volume":"29","author":"Scangos","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119095_bib194","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm2016864","article-title":"Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor","volume":"55","author":"Cid","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib195","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/jm500496m","article-title":"Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor","volume":"57","author":"Cid","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2025.103057","article-title":"TRPV1 signaling in skeletal muscle: a mini review of physiological and pathological roles","volume":"131","author":"Ding","year":"2025","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ejmech.2026.119095_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106392","article-title":"Anti-neuropathic pain activity of Ajugarin-I via activation of Nrf2 signaling and inhibition of TRPV1\/TRPM8 nociceptors in STZ-induced diabetic neuropathy","volume":"183","author":"Khan","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119095_bib198","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/acs.jmedchem.0c00982","article-title":"Discovery of benzopyridone-based transient receptor potential Vanilloid 1 agonists and antagonists and the structural elucidation of their activity shift","volume":"64","author":"Thorat","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib199","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neurol.2025.03.005","article-title":"Epilepsy and Alzheimer disease: new insights and perspectives","volume":"181","author":"Dupont","year":"2025","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejmech.2026.119095_bib200","article-title":"Flavonoids as therapeutic agents for epilepsy: unveiling anti-inflammatory and antioxidant pathways for novel treatments","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib201","doi-asserted-by":"crossref","first-page":"10584","DOI":"10.1021\/jm301268u","article-title":"Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist","volume":"55","author":"Hibi","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib202","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejmech.2026.119095_bib203","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1021\/acs.jmedchem.5c03052","article-title":"Discovery and evaluation of E0714 as an antiepileptic candidate: a highly subtype-selective Kv7 agonist within the Kv7 family designed based on a Kv7.2-Specific pocket","volume":"69","author":"Qiao","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib204","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076161","article-title":"Advances in treatments for acute ischemic stroke","volume":"389","author":"Sharma","year":"2025","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2026.119095_bib205","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jconrel.2021.05.045","article-title":"Novel brain-targeting 3-n-butylphthalide prodrugs for ischemic stroke treatment","volume":"335","author":"Xiang","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119095_bib206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/med.21817","article-title":"Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications","volume":"42","author":"Tuo","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119095_bib207","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1111\/bph.14673","article-title":"Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury","volume":"176","author":"Zhou","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib208","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/molecules22040676","article-title":"Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration","volume":"22","author":"Stockwell","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119095_bib209","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1021\/acsmedchemlett.1c00599","article-title":"Discovery of pyridone-substituted triazolopyrimidine dual A2A\/A1 AR antagonists for the treatment of ischemic stroke","volume":"13","author":"Tang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib210","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1021\/acs.jmedchem.9b01338","article-title":"Development of novel N-hydroxypyridone derivatives as potential anti-ischemic stroke agents","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib211","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.773592","article-title":"Euphorbia factor L2 ameliorates the progression of K\/BxN serum-induced arthritis by blocking TLR7 mediated IRAK4\/IKK\u03b2\/IRF5 and NF-kB signaling pathways","volume":"12","author":"Tang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib212","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.jmedchem.4c01322","article-title":"Interleukin-1 receptor-associated kinase 4 (IRAK4) degraders for treating inflammatory diseases: advances and prospects","volume":"68","author":"Lin","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib213","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/acsmedchemlett.4c00102","article-title":"A tiny pocket packs a punch: leveraging pyridones for the discovery of CNS-penetrant aza-indazole IRAK4 inhibitors","volume":"15","author":"Bolduc","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102842","article-title":"Targeting ITK signaling for T cell-mediated diseases","volume":"24","author":"Weeks","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2026.119095_bib215","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acsmedchemlett.1c00619","article-title":"Dual inhibition of IL-2-Inducible T-Cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) as potential treatment for atopic dermatitis and other inflammatory and autoimmune diseases","volume":"12","author":"Abdel-Magid","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib216","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/jm101499u","article-title":"Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119095_bib218","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-026-01727-9","article-title":"Envudeucitinib, a potent, next-generation, allosteric inhibitor of TYK2: a narrative review","author":"Armstrong","year":"2026","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejmech.2026.119095_bib219","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119095_bib220","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.5b01857","article-title":"Structure-based design and synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivatives as tyrosine kinase 2 inhibitors","volume":"59","author":"Yogo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib221","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib222","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib223","article-title":"Shi Wei Ru Xiang pill alleviates acute gouty arthritis through suppressing NLRP3 inflammasome activation","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112598","article-title":"Euphorbia factor L2 alleviated gouty inflammation by specifically suppressing both the priming and activation of NLRP3 inflammasome","volume":"138","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.119095_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107716","article-title":"Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis","volume":"152","author":"Wu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113583","article-title":"Discovery of chiral N-2'-aryletheryl-1'-alkoxy-ethyl substituted arylisoquinolones with anti-inflammatory activity from the nucleophilic addition reactions of the thiophenols and oxazolinium","volume":"222","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib227","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-026-00687-w","article-title":"Type 2 diabetes mellitus","volume":"12","author":"Davies","year":"2026","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.119095_bib228","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/DDDT.S153898","article-title":"Islet protection and amelioration of type 2 diabetes mellitus by treatment with quercetin from the flowers of Edgeworthia gardneri","volume":"12","author":"Zhuang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.119095_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100397","article-title":"The role of AMPK signaling pathway in the pathogenesis of type 2 diabetes mellitus with its complications and related metabolic disorders","volume":"28","author":"Hunie Tesfa","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.ejmech.2026.119095_bib230","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/ml400157g","article-title":"Discovery of pyridones as oral AMPK direct activators","volume":"4","author":"Mirguet","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib231","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1039\/D4FO06329E","article-title":"The potential effect of polyphenols in emerging pharmacological liver targets for glucose regulation and insulin resistance: a review","volume":"16","author":"Rocha","year":"2025","journal-title":"Food Funct."},{"key":"10.1016\/j.ejmech.2026.119095_bib232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.01.031","article-title":"2-Oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors: design, synthesis and structure-activity relationship study","volume":"111","author":"Loughlin","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib233","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejmech.2016.12.049","article-title":"Discovery of new nanomolar inhibitors of GPa: extension of 2-oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors","volume":"127","author":"Loughlin","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib234","first-page":"841","article-title":"A new flavanone from seeds of Psoralea corylifolia with alpha-Glucosidase inhibitory activity","volume":"13","author":"Liu","year":"2018","journal-title":"Nat. Prod. Commun."},{"key":"10.1016\/j.ejmech.2026.119095_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112034","article-title":"Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes","volume":"188","author":"Luthra","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib236","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/db12-0769","article-title":"Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion","volume":"62","author":"Kimple","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.119095_bib237","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/acsmedchemlett.0c00667","article-title":"Discovery of a novel series of pyridone-based EP3 antagonists for the treatment of type 2 diabetes","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119095_bib238","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117436","article-title":"Discovery of potent, highly selective, and orally bioavailable factor XIa inhibitors for anticoagulant therapy","volume":"289","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118457","article-title":"Design, synthesis and biological evaluation of novel FXIa inhibitors featuring five-membered heterocycles as P2' fragments","volume":"303","author":"Wu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119095_bib241","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia","volume":"17","author":"Luo","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ejmech.2026.119095_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116063","article-title":"Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: from phenotypic hit discovery to in vivo tolerability","volume":"265","author":"Giannessi","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:10:01Z","timestamp":1787040601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":242,"alternative-id":["S0223523426005404"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119095","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Pyridone as privileged scaffold: Advances in drug design and structural modification","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119095"}}